Ipsen Material Announcements

Key highlights

Ipsen completes acquisition of Albireo, expanding the scope of its Rare Disease portfolio

– 02 March 2023 – 1 mins read

02 March 2023 – 1 mins read

Ipsen completes acquisition of Albireo, expanding the scope of its Rare Disease portfolio

PARIS, FRANCE, 3 March 2023 – Ipsen (Euronext: IPN: ADR: IPSEY) today announced it has completed the acquisition of Albireo Pharma, Inc., a leading innovator in bile-acid modulators to treat rare liver conditions. The acquisition enriches Ipsen’s Rare Disease portfolio, with…

Filter

Period

Filter by

Reset

Showing: 1 – 04 of 4 Corporate News

Show

Sort

– 02 March 2023

02 March 2023

Ipsen completes acquisition of Albireo, expanding the scope of its Rare Disease portfolio

Ipsen completes acquisition of Epizyme expanding its portfolio in oncology

– 12 August 2022

12 August 2022

Ipsen completes acquisition of Epizyme expanding its portfolio in oncology

PARIS, FRANCE, 12 August 2022 – Ipsen (Euronext: IPN; ADR: IPSEY) today announced the closing of the definitive merger agreement under which Ipsen has acquired Epizyme, Inc. (Epizyme). Pursuant to the transaction, Ipsen acquires all outstanding shares of Epizyme for $1.45…

Ipsen to acquire Epizyme, expanding its portfolio in oncology

– 27 June 2022

27 June 2022

Ipsen to acquire Epizyme, expanding its portfolio in oncology

PARIS, FRANCE & CAMBRIDGE, MASSACHUSETTS, 27 June 2022 – Ipsen (Euronext: IPN; ADR: IPSEY) and Epizyme (Nasdaq: EPZM) today announced that they have entered into a definitive merger agreement under which Ipsen will acquire Epizyme. The transaction was unanimously approved by…